medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2021, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2021; 19 (4)

Severe Hidradenitis Suppurativa: Clinical-Therapeutic Experience in an Adolescent

Cano-Viveros MI, Sánchez-Cárdenas CD, Godínez-Aldrete L, Pulido-Díaz N

Language: Spanish
References: 20
Page: 338-340
PDF size: 146.12 Kb.


ABSTRACT

Hidradenitis suppurativa (HS) is a chronic inflammatory disease, it presents with friable subcutaneous nodules, purulent discharge, and recurrent fistulas. It is rare in children and adolescents, so the treatment of this group is a challenge, since we do not have treatment guidelines or clinical trials for this population. We present a case of HS in an adolescent male with multiple treatments, who received treatment with adalimumab, presenting a good clinical response and quality of life.


REFERENCES

  1. Saunte ML y Jemec BE, Hidradenitis suppurativa: advances in diagnosis and treatment, jama 2017; 318(20):2019-32. doi: 10.1001/ jama.2017.16691. pmi d: 29183082.

  2. Garg A, Wertenteil S, Baltz R, Strunk A y Finelt N, Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender and age-adjusted population analysis J Invest Dermatol 2018; 138(10):2152-56. doi: 10.1016/j.jid.2018.04.001.

  3. Braunberger TL, Nicholson CL, Gold L, Nahhas AF, Jacobsen G, Parks- Miller A et al., Hidradenitis suppurativa in children: the Henry Ford experience, Pediatr Dermatol 2018; 35(3):370-3. doi: 10.1111/pde.13466.

  4. Liy-Wong C, Pope E y Lara-Corrales I, Hidradenitis suppurativa in the pediatric population, J Am Acad Dermatol 2015; 73(5 Suppl 1):s36-41. doi: 10.1016/j.jaad.2015.07.051.

  5. Bettoli V, Ricci M, Zauli S y Virgili A, Hidradenitis suppurativa-acne inversa: a relevant dermatosis in paediatric patients, Br J Dermatol 2015; 173(5):1328-30. doi: 10.1111/bjd.13951.

  6. Choi E, Ting OX y Chandran NS, Hidradenitis suppurativa in pediatric patients, J Am Acad Dermatol 2020; 18:s0190-9622(20) 32436-1. doi: 10.1016/j.jaad.2020.08.045.

  7. Tricarico PM, Boniotto M, Genovese G, Zouboulis CC, Marzano AV y Crovella S, An integrated approach to unravel hidradenitis suppurativa etiopathogenesis, Front Immunol 2019; 10:892. doi: 10.3389/fimmu. 2019.00892.

  8. Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G et al., Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment, Clin Cosmet Investig Dermatol 2017; 10:105-15. doi: 10.2147/ccid.S111019.

  9. Sabat R, Jemec BE, Matusiak Ł, Kimball AB, Prens E y Wolk K, Hidradenitis suppurativa, Nat Rev Dis Primers 2020; 6(1):18. doi: 10.1038/ s41572-020-0149-1.

  10. Bandera AR y De Lucas Laguna R, Aspectos epidemiológicos, clínicos y terapéuticos en situaciones especiales: hidradenitis supurativa infantil Actas Dermo-Sifiliográficas 2016; 107:51-60.

  11. Danby FW, Current concepts in the management of hidradenitis suppurativa in children, Curr Opin Pediatr 2015; 27:466-72.

  12. Goldburg SR, Strober BE y Payette MJ, Hidradenitis suppurativa: current and emerging treatments, J Am Acad Dermatol 2020; 82(5):1061- 82. doi: 10.1016/j.jaad.2019.08.089.

  13. Nguyen QD, Starling CT y Hebert AA, The use of tnf-α inhibitors in treating pediatric skin disorders, Paediatr Drugs 2020; 22(3):311-9. doi: 10.1007/s40272-020-00394-3.

  14. Flood KS, Porter ML y Kimball AB, Biologic treatment for hidradenitis suppurativa, Am J Clin Dermatol 2019; 20(5):625-38. doi: 10.1007/ s40257-019-00439-5.

  15. Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G et al., Evidence for a “window of opportunity” in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study, Br J Dermatol 2020. doi: 10.1111/bjd.18983.

  16. Tzanetakou V, Stergianou D y Giamarellos-Bourboulis EJ, Longterm safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa, Expert Opin Drug Saf 2020;19(4):381-93. doi: 10.1080/14740338.2020.1734560.

  17. Van der Zee HH y Gulliver WP, Medical treatments of hidradenitis suppurativa: more options, less evidence, Dermatol Clin 2016; 34(1):91- 6. doi: 10.1016/j.det.2015.08.006.

  18. Khandalavala BN y Do MV, Finasteride in hidradenitis suppurativa: a “male” therapy for a predominantly “female” disease, J Clin Aesthet Dermatol 2016; 9(6):44-50. Epub 2016 Jun 1. pmi d: 27386051; pm cid: pm c4928456.

  19. Wortsman X, Rodríguez C, Lobos C, Eguiguren G y Molina MT, Ultrasound diagnosis and staging in pediatric hidradenitis suppurativa. Pediatr Dermatol 2016; 33(4):e260-4. doi: 10.1111/pde.12895.

  20. Jalenques I, Ciortianu L, Pereira B, D’Incan M, Lauron S y Rondepierre F, The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: systematic review and meta-analysis, J Am Acad Dermatol 2020; 83(2):542-53. doi: 10.1016/j. jaad.2020.03.041.




2020     |     www.medigraphic.com